May 25, 2022

Volume XII, Number 145

Advertisement
Advertisement

May 24, 2022

Subscribe to Latest Legal News and Analysis

May 23, 2022

Subscribe to Latest Legal News and Analysis
Advertisement

HHS Abandons Proposal to Reform Drug Manufacturer Rebate System

On Thursday, July 11, 2019, the White House administration reversed course on the Department of Health and Human Services’ (HHS) recent proposal to reform drug manufacturer rebate system. As we previously reported, HHS’s February 6, 2019 proposed rule sought to modify the Anti-Kickback Statute safe harbor protection with the aim of lowering prescription pharmaceutical product prices and out-of-pocket costs for consumers (primarily Medicare Part D and Medicaid Managed Care Plan members). With the proposed rule, HHS hoped to encourage medication manufacturers to pass discounts directly to consumers and develop a transparent framework for the prescription drug product market.

The public comment period for the proposed rule closed at midnight on April 8, 2019, with over 25,000 comments received. The pharmaceutical industry welcomed the proposed rule. Pharmaceutical Research and Manufacturers of America (PhRMA) informed HHS in April that it considers the proposed reform of the rebate system to be urgent. On the other hand, payers, pharmacy benefit manager and providers have opposed the proposal, collectively warning that the elimination of the safe harbors could lead to higher costs for patients.

According to several reports, the administration’s decision to back away from the proposed rule is based on the prospects of bipartisan legislation aimed at reducing drug costs, as well a concern that the proposed rule would have imposed increased drug costs on seniors. In a May 2019 report, the Congressional Budget Office estimated that the proposed rule would increase federal spending by about $177 billion from 2020 to 2029, with increases in Medicare Part D plan premiums.   HHS officially withdrew notice of its pending final rule on July 10, 2019.

© Copyright 2022 Squire Patton Boggs (US) LLPNational Law Review, Volume IX, Number 198
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement

About this Author

Squire Patton Boggs's Healthcare Industry Group provides exceptional legal, regulatory, transactional, legislative and strategic counsel on a wide range of industry issues to healthcare-related entities around the globe. Their transactional specialists have completed hundreds of deals across the industry, ranging from company formation, to mergers, acquisitions, and divestitures, and from corporate, public or project finance matters, through to workouts. Their litigators have extensive experience advocating for their clients in courts and arbitrations across the nation and have helped to...

614-365-2717
Advertisement
Advertisement
Advertisement